The use of acarbose inhibition in the measurement of acid alpha-glucosidase activity in blood lymphocytes for the diagnosis of Pompe disease

Genetics in Medicine

Volumn 8, Issue 5, 2006, Pages 307-312

  Jack, Rhona M ^a   Gordon, Cindy ^a   Scott, C R ^c   Kishnani, Priya S ^b   Bali, Deeksha ^b  

^a SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Acid alpha glucosidase; GAA; Lymphocytes; Pompe disease; Pompe enzyme diagnosis

Indexed keywords

ACARBOSE; GLUCAN 1,4 ALPHA GLUCOSIDASE; ALPHA GLUCOSIDASE; ENZYME INHIBITOR; GAA PROTEIN, HUMAN;

ARTICLE; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; FIBROBLAST; GLYCOGEN STORAGE DISEASE TYPE 2; HUMAN; HUMAN TISSUE; INFANT; LABORATORY; LYMPHOCYTE; BLOOD; DRUG ANTAGONISM; ENZYMOLOGY; EVALUATION; METHODOLOGY;

ACARBOSE; ALPHA-GLUCOSIDASES; ENZYME INHIBITORS; ENZYME TESTS; GLYCOGEN STORAGE DISEASE TYPE II; HUMANS; INFANT; LYMPHOCYTES;

EID: 33745585382     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.gim.0000217785.19262.9e     Document Type: Article

References (24)

1. th edition. Scriver CR, Beaudet AL, Sly WS, Valle D (Eds). New York: McGraw-Hill 2001:3389-3420.
2. Kishnani P, Howell R. Pompe disease in infants and children. J Pediatr 2004;144:S35-S43.
3. Marsden D. Infantile Pompe disease: A report of physician narratives from an epidemiologic study. Genet Med 2005;7:147-150.
4. Kishnani P, Hwu W, Mandel H, Nicolino M, et al. On behalf of the infantile-onset Pompe disease natural history study group; a retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr (in press).
5. Van den Hout HM, Hop W, van Diggelen OP, Smeitink JA, et al. The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. Pediatrics 2003;112:332-340.
6. Martiniuk F, Chen A, Mack A, Arvanitopoulos E, et al. Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease. Am J Med Genet 1998;79:69-72.
7. Ausems MG, Verbiest J, Hermans MP, Kroos MA, et al. Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counseling. Eur J Hum Genet 1999;7:713-716.
8. Taniguchi N, Kato E, Yoshida H, Iwaki S, et al. Alpha-glucosidase activity in human leucocytes: choice of lymphocytes for the diagnosis of Pompe's disease and the carrier state. Clin Chim Acta 1978;89:293-299.
9. Dreyfus J, Poenaru L. White blood cells and the diagnosis of alpha-glucosidase deficiency. Pediatr Res 1980;14:342-344.
10. Lavrenova T, Presnova V. Rat liver neutral alpha-glucosidase: isolation and characterization. Biochem Mol Biol Int 1994;32:671-679.
11. Shapira E, Blitzer M, Miller J, Africk D. Biochem Genet, A Laboratory Manual. New York:Oxford University Press;1989;26.
12. Reuser AJ, Koster JF, Hoogeveen A, Galjaard H. Biochemical, immunological, and cell genetic studies in glycogenosis type II. Am J Hum Genet 1978;30:132-143.
13. Hermans MM, Kroos MA, van Beeumen J, Oostra BA et al. Human lysosomal alpha-glucosidase: Characterization of a catalytic site. J Biol Chem 1991;266:13507-13512.
14. Van Hove JL, Yang HW, Wu JY, Brady RO, et al. High level production of recombinant human lysosomal acid alpha-glucosidase in Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblasts from patients with Pompe disease. Proc Natl Acad Sci U S A 1996;93:65-70.
15. Desnick RJ. Enzyme replacement and enhancement therapies for lysosomal diseases. J Inherit Metab Dis 2004;27:385-410.
16. Klinge L, Straub V, Neudorf U, Voit T. Enzyme replacement therapy in classical infantile Pompe disease: results of a ten month follow up study. Neuropediatrics 2005;36:6-11.
17. Amalfitano A, Bengur AR, Morse RP, Majure JM. Recombinant human acid (alpha)-glucosidase enzyme therapy for infantile glycogen storage disease type II: Results of a phase I/II clinical trial. Genet Med 2001;3:132-138.
18. Van den Hout H, Reuser AJ, Vulto AG, Loonen MC, et al. Recombinant human alpha-glucosidase from rabbit milk in Pompe patients. Lancet 2000;356:397-398.
19. Van den Hout JM, Reuser AJ, de Klerk JB, Arts WF, et al. Enzyme therapy for Pompe disease with recombinant human alpha-glucosidase from rabbit milk. J Inherit Metab Dis 2001;24:266-274.
20. Kishnani PS, Nicolino M, Rogers RC, Tsai ACH, et al. Results from a phase II trial of Chinese hamster ovary cell-derived recombinant human acid α-glucosidase in infantile-onset Pompe disease. J Pediatr (in press).
21. Ing RJ, Cook DR, Bengur RA, Williams EA, et al. Anaesthetic management of infants with glycogen storage disease type II: a physiological approach. Paediatr Anaesth 2004;14:514-519.
22. Chamoles NA, Niizawa G, Blanco M, Gaggioli D, et al. Glycogen storage disease type II: enzymatic screening in dried blood spots on filter paper. Clin Chim Acta 2004;347:97-102.
23. Li Y, Scott CR, Chamoles NA, Ghavami A, et al. Direct multiplex assay of lysosomal enzymes in dried blood spots for newborn screening. Clin Chem 2004;50:1785-1796.
24. Umapathysivam K, Whittle AM, Ranieri E, Bindloss C, et al. Determination of acid (alpha)-glucosidase protein: evaluation as a screening marker for Pompe disease and other lysosomal storage disorders. Clin Chem 2000;46:1318-1325.